MedTrace Logo

Effects of Cannabis on Prescription Drug Abuse Liability and Analgesia

NCT03679949 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2024-12-05

No results posted yet for this study

Summary

The purpose of this research is to assess the impact of cannabis on the analgesic and abuse-liability effects of a sub-threshold dose of a commonly used analgesic.

Conditions

Interventions

DRUG

Oxycodone

Oxycodone, 2.5 mg

DRUG

Cannabis (THC:CBD = ~ 1:0)

Cannabis with high THC concentration and negligible CBD concentrations

DRUG

Cannabis (THC:CBD = ~ 0:1)

Cannabis with high CBD concentration and negligible THC concentrations

DRUG

Cannabis (THC:CBD = ~ 1:1)

Cannabis with equivalent CBD and THC concentrations

DRUG

Placebo

Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone

Sponsors & Collaborators

  • New York State Psychiatric Institute

    lead OTHER

Principal Investigators

  • Caroline A Cooper, PhD · New York Psychiatric Institute

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
53 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2022-12-06
Completion
2022-12-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03679949 on ClinicalTrials.gov